User:Mr. Ibrahem/Dinutuximab

Dinutuximab, sold under the trade name Unituxin among others, is a medication used to treat neuroblastoma. It is used for children at high-risk who are still having problems despite other treatments. It is given by injection into a vein.

Common side effects include pain, fever, infusion reaction, low platelets, low white blood cells, low potassium, capillary leak syndrome, and liver problems. Other side effects may include reversible posterior leukoencephalopathy syndrome, transverse myelitis, eye problems, and infection. Use in pregnancy may harm the baby. It is a monoclonal antibody that attaches to GD2, commonly found on neuroblastoma cells. This binding causes the body's immune system to destroy them.

Dinutuximab was approved for medical use in the United States in 2015. While it was also approved in Europe in 2015, it was subsequently withdrawn in 2017. Dinutuximab beta; however, received approval in Europe in 2017. In the United States 17.5 mg costs about 14,000 USD as of 2021.